CSTL (Castle Biosciences, Inc.) Stock Financials & Earnings

CSTLCastle Biosciences, Inc.

Mkt Cap$805M

Revenue (TTM)$344M

Net Income (TTM)-$24M

EPS (TTM)-$0.85

Free Cash Flow (TTM)$28M

Gross Margin68.7%

Op. Margin-12.4%

Net Margin-7.0%

FCF Margin8.2%

P/S Ratio (TTM)2.3x

P/E Ratio (TTM)—

YoY Rev Growth+3.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$42M	$32M	-$32M
Q2 23	$50M	$39M	-$21M
Q3 23	$61M	$50M	-$10M
Q4 23	$66M	$54M	-$6M
Q1 24	$73M	$59M	-$5M
Q2 24	$87M	$72M	$5M
Q3 24	$86M	$70M	$5M
Q4 24	$86M	$70M	$4M
Q1 25	$88M	$72M	-$28M
Q2 25	$86M	$69M	-$4M
Q3 25	$83M	$64M	-$7M
Q4 25	$87M	$32M	-$4M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$14M	$17M	$30M	—
Q2 23	$13M	$16M	$28M	—
Q3 23	$13M	$16M	$28M	—
Q4 23	$13M	$17M	$27M	—
Q1 24	$14M	$18M	$31M	—
Q2 24	$14M	$18M	$33M	—
Q3 24	$12M	$21M	$30M	—
Q4 24	$12M	$20M	$30M	—
Q1 25	$13M	$22M	$37M	—
Q2 25	$13M	$23M	$35M	—
Q3 25	$13M	$23M	$33M	—
Q4 25	$14M	—	—	$57M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$115M	$117M	$232M
Q2 23	$96M	$130M	$226M
Q3 23	$91M	$139M	$230M
Q4 23	$99M	$144M	$243M
Q1 24	$83M	$156M	$239M
Q2 24	$86M	$174M	$260M
Q3 24	$95M	$185M	$280M
Q4 24	$120M	$173M	$293M
Q1 25	$90M	$185M	$275M
Q2 25	$82M	$194M	$276M
Q3 25	$86M	$202M	$288M
Q4 25	$117M	$183M	$300M

Shares Outstanding

Revenue Per Employee

Revenue / Employee